Evaluation of efficacy and safety of perampanel in post-operative glioma patients with epilepsy

Evaluation of efficacy and safety of perampanel in post-operative glioma patients with epilepsy - Evaluation of efficacy and safety of perampanel in post-operative glioma patients with epilepsy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026095

Enrollment

Registered

2017-02-13

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioma

Interventions

add 8 mg of PER on the patients treated with 1000mg of LEV for 1 year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)age of 20/<= and <=75 2)no neoplasm detected by MRI on optic nerve or pituitary 3)no multiple region or dissemination of the glioma on MRI 4)glioma confirmed by pathological examination on surgery 5)no past-history of chemotherapy or radiotherapy for other malignant disease 6)obtained the consent in writing from the patient

Exclusion criteria

Exclusion criteria: 1)patients with contraindication of perampanel or levetiracetam 2)inadequate patient judged by the investigator 3)pregnant woman

Design outcomes

Primary

Measure	Time frame
Seizure free rate (Time Frame: 12 months after treatment)	—

Secondary

Measure	Time frame
PFS and OS of glioma patients	—

Countries

Japan

Contacts

Public ContactShuichi Izumoto

Kindai University School of Medicine Department of Neurosurgery

sizumoto@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026